USSN 10/804,532 Non-final Office Action dated 09 January 2007 Response dated 09 May 2007

## Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## 1-13. (canceled)

14. (currently amended) A transgenic mouse comprising an altered or deleted endogenous a deletion of the Calcium Independent Receptor of Latrotoxin 3–Like (CIRL3-L) gene, characterized by exhibiting wherein the transgenic mouse exhibits at least one diagnostic criterion of a psychiatric disorder that is an anxiety-related disorder[[s]] selected from Asperger's syndrome, autism, and pervasive developmental disorder-not otherwise specified (PDD NOS).

## 15. - 26. (canceled)

- 27. (new) The transgenic mouse according to claim 14, wherein the transgenic mouse exhibits at least one diagnostic criterion for Asperger's syndrome.
- 28. (new) The transgenic mouse according to claim 27, wherein the transgenic mouse exhibits at least two diagnostic criteria for Asperger's syndrome.
- 29. (new) The transgenic mouse according to claim 14, wherein the transgenic mouse meets at least one diagnostic criterion for autism.
- (new) The transgenic mouse according to claim 29, wherein the transgenic mouse meets at least two diagnostic criteria for autism.
- (new) The transgenic mouse according to claim 14, wherein the transgenic mouse meets
  at least one diagnostic criterion for pervasive developmental disorder-not otherwise specified
  (PDD-NOS).
- (new) The transgenic mouse according to claim 31, wherein the transgenic mouse meets
  at least two diagnostic criteria for pervasive developmental disorder-not otherwise specified
  (PDD-NOS).